Lung Cancer | Expert Second Opinion: The Emerging Role of Immunotherapy and Targeted Treatment in Localized Non-Small Cell Lung Cancer

Featuring perspectives from Drs Edward Garon, Jarushka Naidoo, Harvey Pass and Heather Wakelee, including the following topics: Immunotherapy in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC) Introduction: Tumor board discussions since ASCO 2021 (0:00) Case: A woman in her early 60s with Stage IIA lung adenocarcinoma — PD-L1-negative, pan-wild type (8:00) Case: A man in his mid-50s with Stage IIA squamous NSCLC — PD-L1 15% (22:44) Case: A man in his early 90s with Stage IB lung adenocarcinoma — PD-L1 10% (31:47) Key relevant data sets (39:07) Adjuvant Treatment of NSCLC with a Driver Mutation Case: A man in his late 60s with Stage III lung adenocarcinoma — PD-L1 Case: A woman in her late 40s with Stage IIIA lung adenocarcinoma — PD-L1 50%, ALK mutation (53:53) CME information and select publications